Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
120 patient acebilustat early treatment RCT: 80% lower progression (p=0.21), 67% worse recovery (p=0.07), and 6% improved viral clearance.
RCT 120 outpatients showing no significant difference in time to sustained symptom resolution or viral clearance with acebilustat treatment. Subgroup analyses showed consistent patterns of longer symptom duration in treated participants.
Mar 2023, Clinical Infectious Diseases, https://academic.oup.com/cid/article/77/2/186/7095671, https://c19p.org/levitt
